Jef Akst, "The Scientist.com"
Jan.6, 2010
Want to go to Central America for free? All it takes is your participation in a clinical trial for a diarrhea vaccine. A patch worn on the arm can earn you a complimentary trip to one of nine cities in Mexico and Guatemala, courtesy of Intercell AG.
The Austrian drug company is recruiting 1800 volunteers for the phase III clinical trial of a vaccine against enterotoxigenic Escherichia coli -- a major cause of traveler's diarrhea, which affects about 20 million visitors to countries such as Africa, Asia and Latin America, as well as illness in more than 200 million children living in those countries each year. If approved, it would be the first vaccine for traveler's diarrhea available in the US.
A couple years ago, we looked at the question of how researchers and companies decide on compensation for subjects' participation in clinical trials. But the trip offered by the Austrian company seems to be an entirely new recruitment tactic, the BMJ reports.
Intercell joined forces with Inclinix, Inc., a North Carolina-based clinical trial enrollment solutions provider, to devise a strategy including partnerships with major travel and tourism websites, as well as a variety of social networking outlets, including Twitter and YouTube. "Social communication avenues allow Inclinix to reach a unique audience," Diane Montross, director of patient recruitment for Inclinix, told Medical News Today. "We are defining the next patient recruitment landscape."
In addition to the flight to Central America, participants will receive at least six nights of three star accommodations, pre-paid mobile phones, welcome kits with useful travel tools, and $1,500 in cash upon completion of the study. Participants will be given either the active vaccine or a placebo before travel, give blood within 48 hours of arrival, keep a stool diary throughout their trip, and provide additional blood and stool samples if they develop diarrhea.
Jan.6, 2010
Want to go to Central America for free? All it takes is your participation in a clinical trial for a diarrhea vaccine. A patch worn on the arm can earn you a complimentary trip to one of nine cities in Mexico and Guatemala, courtesy of Intercell AG.
The Austrian drug company is recruiting 1800 volunteers for the phase III clinical trial of a vaccine against enterotoxigenic Escherichia coli -- a major cause of traveler's diarrhea, which affects about 20 million visitors to countries such as Africa, Asia and Latin America, as well as illness in more than 200 million children living in those countries each year. If approved, it would be the first vaccine for traveler's diarrhea available in the US.
A couple years ago, we looked at the question of how researchers and companies decide on compensation for subjects' participation in clinical trials. But the trip offered by the Austrian company seems to be an entirely new recruitment tactic, the BMJ reports.
Intercell joined forces with Inclinix, Inc., a North Carolina-based clinical trial enrollment solutions provider, to devise a strategy including partnerships with major travel and tourism websites, as well as a variety of social networking outlets, including Twitter and YouTube. "Social communication avenues allow Inclinix to reach a unique audience," Diane Montross, director of patient recruitment for Inclinix, told Medical News Today. "We are defining the next patient recruitment landscape."
In addition to the flight to Central America, participants will receive at least six nights of three star accommodations, pre-paid mobile phones, welcome kits with useful travel tools, and $1,500 in cash upon completion of the study. Participants will be given either the active vaccine or a placebo before travel, give blood within 48 hours of arrival, keep a stool diary throughout their trip, and provide additional blood and stool samples if they develop diarrhea.